Real World Study of Platinum Containing Dual Drug Chemotherapy Followed by Large Fractionated Radiotherapy Combined withTislelizumab in Stage IIIB/C-IV Non-small Cell Lung Cancer Patient

In clinical practice, some patients cannot tolerate concurrent chemoradiotherapy. The purpose of this study is to observe the efficacy and safety of platinum-based doublet chemotherapy followed by hypofractionated radiotherapy and Tislelizumab in patients with stage IIIB/C-IV non-squamous non-small cell lung cancer. This study aims to provide more treatment options for patients with locally advanced non-small cell lung cancer.

NCT Number	NCT07198217
Lead Sponsor	Zibo Municipal Hospital
Conditions	NSCLC, Tislelizumab, Chemotherapy, Hypofractionated Radiotherapy
Enrollment	20 participants
Start Date	2021-05-25
Primary Completion	2025-09-28 (estimated)
Study Completion	2027-10-10 (estimated)
Updated on ClinicalTrials.gov	2025-09-30